HealthQuill CAR T-cell therapy
An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the patients with a fatal form of brain cancer.
Drugs Health Pharma

Gilead unit’s experimental therapy shrink brain tumours by 62%

HQ Team June 2, 2025: An investigational therapy from Kite Pharma Inc., a Gilead Sciences company, has reduced tumours in 62% of the.

Read More
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Medical

New CAR T-cell therapy offers hope for children with aggressive blood cancer

HQ Team October 14, 2024: Children with aggressive blood cancer may soon have access to a new treatment, CAR T-cell therapy, targeting T-cell.

Read More